AsiaNet 63087

モンペリエ(フランス)、2016年2月4日/PRニュースワイヤー/ —





当契約では、対象のAPI(医薬品有効成分)を特許所有のMedinCell BEPO(TM)技術プラットフォームを使用して調合します。BEPOにより、投薬回数を削減、また患者の忍容性を潜在的に改善するため、直接、間接の薬剤費を削減することにもなります。

この提携では、BEPOの破壊的特性から利益を得ます。優れた薬物放出制御、商品の低価格、迅速な製剤開発などです。BEPOの多様なプラットフォームは、多くの低分子、ペプチド、生物製剤などに適合します。両社ともに、MedinCell とコルビオンの新規合弁会社であるCMバイオマテリアルズを通して、GMPグレードのポリマーが入手可能になります。




詳細は、http://www.medincell.com までご参照ください。

問合せ先: David Heuze – david.heuze@medincell.com / +33-(0)6-83-25-21-86

情報源: MedinCell


MedinCell Enters Into a Technology Agreement for Long-Acting Injectable Products


MONTPELLIER, France, Feb. 4, 2016 /PRNewswire=KYODO JBN/ —

     – MedinCell and Sandoz will develop and commercialize long-acting
injectable products based on BEPO(TM) technology with a primary focus on
     – The alliance is part of MedinCell’s network strategy to significantly
improve current standard of care, reduce total costs to payers and therefore
make treatments widely available worldwide

    MedinCell, a leading innovator developing best in class enabling
pharmaceutical solutions for Global Health, announced today that it has entered
into a non-exclusive collaboration agreement with Sandoz, a Novartis company.

(Logo: http://photos.prnewswire.com/prnh/20160201/327836LOGO )

    Both parties will join forces to develop and commercialize long-acting
injectables with a primary focus on oncology. The first product has been
selected and development efforts are underway.

    Under the agreement, target APIs (Active Pharmaceutical Ingredients) will
be formulated using the proprietary MedinCell BEPO(TM) technology platform.
BEPO may allow less frequent drug administration and potentially improved
patient tolerability, which may reduce both direct and indirect drug costs.

    The alliance will benefit from BEPO’s disruptive characteristics: superior
controlled drug release, low cost of goods and rapid formulation development.
BEPO’s versatile platform is compatible with many small molecules, peptides and
biologics. Both parties will have access to GMP-grade polymers through the
newly formed joint venture between MedinCell S.A. and Corbion N.V., CM

    About BEPO(TM)

    Based on a combination of co-polymers, solvent and API, the BEPO(TM)
technology can provide a controlled release of drug for days, weeks or months
from a fully biodegradable depot that forms after subcutaneous injection or
local delivery of the formulated API. As a game-changing technology, BEPO(TM)
combines many advantages compared to alternative drug delivery technologies,
including improved patient compliance, efficacy and tolerability, as well as
versatility, speed of development and low manufacturing costs.

    See how it works:

    MedinCell: Innovations for Global Health

    The MedinCell team acts every day for Global Health by developing
innovative technologies that improve worldwide access to medicine and enable
better treatment quality for all. MedinCell and its network of partners are
developing the next generation of best-in-class medicines that combine low
manufacturing cost with efficiency and compliance-related attributes. Based in
Montpellier, France, MedinCell is a self-funded and employee-owned entity
operating both commercial and non-profit activities.

    For more information: http://www.medincell.com

    Contact: David Heuze – david.heuze@medincell.com / +33-(0)6-83-25-21-86

SOURCE: MedinCell